JP2014525463A5 - - Google Patents

Download PDF

Info

Publication number
JP2014525463A5
JP2014525463A5 JP2014528672A JP2014528672A JP2014525463A5 JP 2014525463 A5 JP2014525463 A5 JP 2014525463A5 JP 2014528672 A JP2014528672 A JP 2014528672A JP 2014528672 A JP2014528672 A JP 2014528672A JP 2014525463 A5 JP2014525463 A5 JP 2014525463A5
Authority
JP
Japan
Prior art keywords
inflammatory
pharmaceutical composition
disease
disorder
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525463A (ja
JP6109175B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/053533 external-priority patent/WO2013033642A1/en
Publication of JP2014525463A publication Critical patent/JP2014525463A/ja
Publication of JP2014525463A5 publication Critical patent/JP2014525463A5/ja
Application granted granted Critical
Publication of JP6109175B2 publication Critical patent/JP6109175B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528672A 2011-09-01 2012-08-31 酸化リン脂質の製剤および剤形 Expired - Fee Related JP6109175B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161529989P 2011-09-01 2011-09-01
US61/529,989 2011-09-01
PCT/US2012/053533 WO2013033642A1 (en) 2011-09-01 2012-08-31 Formulations and dosage forms of oxidized phospholipids

Publications (3)

Publication Number Publication Date
JP2014525463A JP2014525463A (ja) 2014-09-29
JP2014525463A5 true JP2014525463A5 (cg-RX-API-DMAC7.html) 2015-10-01
JP6109175B2 JP6109175B2 (ja) 2017-04-05

Family

ID=46964020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528672A Expired - Fee Related JP6109175B2 (ja) 2011-09-01 2012-08-31 酸化リン脂質の製剤および剤形

Country Status (15)

Country Link
US (3) US9254297B2 (cg-RX-API-DMAC7.html)
EP (1) EP2750668B1 (cg-RX-API-DMAC7.html)
JP (1) JP6109175B2 (cg-RX-API-DMAC7.html)
KR (1) KR101939430B1 (cg-RX-API-DMAC7.html)
CN (1) CN103874485B (cg-RX-API-DMAC7.html)
AU (1) AU2012301602B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014004916B1 (cg-RX-API-DMAC7.html)
CA (1) CA2847218C (cg-RX-API-DMAC7.html)
EA (1) EA029274B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768266T3 (cg-RX-API-DMAC7.html)
IL (1) IL231222B (cg-RX-API-DMAC7.html)
MX (1) MX357759B (cg-RX-API-DMAC7.html)
SG (1) SG11201400208PA (cg-RX-API-DMAC7.html)
WO (1) WO2013033642A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401478B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US9006217B2 (en) 2007-01-09 2015-04-14 Vascular Biogenics Ltd. High-purity phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
SG11201400208PA (en) * 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids
US9771385B2 (en) 2014-11-26 2017-09-26 Vascular Biogenics Ltd. Oxidized lipids
CN106999506A (zh) 2014-11-26 2017-08-01 脉管生物生长有限公司 氧化脂质以及纤维化的治疗或预防
US10597603B2 (en) 2014-12-16 2020-03-24 Polymer Ventures, Inc. Oil recovery aid
PY1576960A (es) * 2014-12-16 2017-12-01 Polymer Ventures Auxiliar de recuperación de aceite
JP6755530B2 (ja) * 2016-09-02 2020-09-16 国立大学法人岩手大学 皮膚炎の予防又は治療用医薬組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
US4970233A (en) * 1987-08-04 1990-11-13 Mchugh John E Treatment of Acquired Immunodeficiency Syndrome (AIDS) HTLV-111/LAV infections and Acquired Immunodeficiency Syndroms (AIDS) Related Complex (ARC)
WO2002053092A2 (en) 2001-01-04 2002-07-11 Vascular Biogenics Ltd. Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
IL156015A0 (en) 2000-11-24 2003-12-23 Vascular Biogenics Ltd Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6838452B2 (en) * 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US20060258692A1 (en) * 2002-10-31 2006-11-16 Mark Pines Quinazolinone compositions for regulation of gene expression related to pathological processes
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
NZ553147A (en) 2004-07-09 2010-07-30 Vascular Biogenics Ltd Improved process for the preparation of oxidized phospholipids
US7807847B2 (en) 2004-07-09 2010-10-05 Vascular Biogenics Ltd. Process for the preparation of oxidized phospholipids
US8569529B2 (en) 2007-01-09 2013-10-29 Vascular Biogenics Ltd. High-purity phospholipids
US8999960B2 (en) 2008-10-08 2015-04-07 Vascular Biogenics Ltd. Oxidized thiophospholipid compounds and uses thereof
KR20110095288A (ko) 2008-11-06 2011-08-24 바스큘라 바이오제닉스 리미티드 산화된 지질 화합물 및 이의 용도
JP2013516455A (ja) 2010-01-05 2013-05-13 バスキュラー バイオジェニックス リミテッド Vb−201を用いた治療
SG11201400208PA (en) 2011-09-01 2014-03-28 Vascular Biogenics Ltd Formulations and dosage forms of oxidized phospholipids

Similar Documents

Publication Publication Date Title
CN115054586B (zh) 改性的释放制剂
ES2731881T3 (es) Composiciones que comprenden compuestos activos lipófilos y método para su preparación
JP6034000B2 (ja) スフィンゴシン−1−リン酸(s1p)受容体モジュレーターを含む組成物
CN103998037B (zh) 对高熔点疏水性化合物具有改进的生物利用度的药物组合物
AU2014210103B2 (en) Pharmaceutical composition with improved bioavailability
CN112912067B (zh) 儿童剂型、制造和使用方法
CN103874485B (zh) 氧化的磷脂的制剂和剂型
KR20160093611A (ko) 경구 투여를 위한 약물 제제의 제조 방법
CN107847490A (zh) 改进的地拉罗司制剂及制备其的方法
TW201206903A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzi midazol-2-yl]-1H-quinolin-2-one lactate monohydrate
JP2018516979A (ja) Somcl−9112固体分散体、その製造方法およびそれを含むsomcl−9112固体製剤
JP2010538062A5 (cg-RX-API-DMAC7.html)
US20150118296A1 (en) Controlled release budesonide compositions
KR20090031618A (ko) 나노입자형 모다피닐 제제
EP2874608A1 (en) Dry granulates of mesoporous silica powders
CN111511365A (zh) 改进的药物制剂
ES2932626T3 (es) Composición farmacéutica que comprende Aprepitant y método para su preparación
JP2010521494A (ja) 麻薬性および非麻薬性鎮痛剤の組み合わせ
TWI859242B (zh) 嘧啶基胺基-吡唑化合物之修飾釋放調配物及治療方法
TW202320774A (zh) 用於口服之舒緩肽b2受體拮抗劑之基於脂質之組成物
CN107281106A (zh) 胆酸盐修饰的阳离子维生素d3口服脂质体及其冻干制剂
CN103142518B (zh) 一种阿格列汀脂质体固体制剂及其制备方法和应用
CN114206319B (zh) 用于治疗hbv的药物组合物
WO2025262137A1 (en) Formulations comprising crystalline nanosized encorafenib
HK40079809A (en) Modified release formulations